The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 23, 2021
Filed:
Nov. 27, 2019
Applicant:
Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;
Inventors:
Tomoyuki Igawa, Shizuoka, JP;
Atsuhiko Maeda, Shizuoka, JP;
Kenta Haraya, Shizuoka, JP;
Tatsuhiko Tachibana, Shizuoka, JP;
Yuki Iwayanagi, Shizuoka, JP;
Yuji Hori, Shizuoka, JP;
Genki Nakamura, Shizuoka, JP;
Masaru Muraoka, Shizuoka, JP;
Assignee:
Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 16/24 (2006.01); C07K 16/36 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); C07K 16/42 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C07K 16/244 (2013.01); C07K 16/18 (2013.01); C07K 16/2866 (2013.01); C07K 16/36 (2013.01); C07K 16/40 (2013.01); C07K 16/4291 (2013.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); G01N 2500/04 (2013.01);
Abstract
One nonexclusive aspect provides molecules further improved from antibodies that can bind to antigens in an ion concentration-dependent manner. An alternative nonexclusive aspect provides safe and more advantageous Fc region variants that have decreased binding to pre-existing ADA. An alternative nonexclusive aspect provides novel IL-8 antibodies that are superior as pharmaceuticals.